The Promising Pathway Act is designed to incentivize companies to offer patients the freedom to use not-yet-approved drugs.
The legislation could be a game-changer.
(BPT) - Glioblastoma (GBM) is the most common, complex, treatment-resistant and deadliest type of brain cancer with 13,400 new cases diagnosed in the U.S. each year. On GBM Awareness Day on July 20, it’s important to raise public awareness of thi.
David Zagzag, MD, Ph.D. of Rego Park, New York has been recognized as an Honored Member for 2022 by Strathmore’s Who’s Who Worldwide Edition for.
My Husband's Lost Balance Turned Out to Be a Brain Tumor Symptom prevention.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prevention.com Daily Mail and Mail on Sunday newspapers.
Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
January 08, 2021 06:00 ET | Source: Chimerix, Inc. Chimerix, Inc.
ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma
Compelling Response Rates to Date; Defined Regulatory Path to Registration Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million
Management to Host Conference Call at 8:30 a.m. ET Today
DURHAM, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has acquired Oncoceutics, Inc., a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics’ lead product candidate, ONC201, has been shown in clinical testing to selectively induce c